Search Bar & Filters
Found 8 Actively Recruiting clinical trials
Actively Recruiting
Researchers are studying the effects of ACM-001.1, a drug taken alongside semaglutide, on muscle loss and muscle gain in adults with obesity. Semaglutide is already approved for weight management, but it can cause loss of muscle mass. This phase 2a study aims to assess how ACM-001.1 impacts lean body mass during and after semaglutide treatment in obese patients. The study consists of two 20-week parts separated by a 4-week break without treatment. Participants receive either semaglutide injections or sham fake injections weekly, alongside oral tablets of ACM-001.1 or placebo, taken twice daily. Two doses of ACM-001.1 are tested, and participants are randomly assigned to different groups in a crossover design to compare the effects during semaglutide therapy and after stopping semaglutide. Participants will undergo DEXA scans to measure body composition, heart tests, muscle function tests including handgrip strength, and complete health questionnaires. Blood samples will be collected to monitor overall health. The main outcome is the change in lean body mass during and after semaglutide treatment. The total study duration is about 18 months with close monitoring and questionnaires throughout.
Actively Recruiting
Researchers are evaluating how a decentralized treatment model affects treatment adherence among participants with early-stage HER2-positive breast cancer. The study compares two groups one where participants do not experience increased travel burden for adjuvant therapy, and another where participants must travel from secondary to tertiary centers for treatment. The goal is to understand how travel impacts adherence and quality of life in routine clinical practice without study-mandated interventions. Participants are assigned to one of four cohorts based on their treatment history and residence. Some receive adjuvant therapy at secondary or tertiary centers, depending on their pathological response after neoadjuvant therapy or if they missed neoadjuvant therapy and had surgery first. All decisions about treatment occur as part of usual care, with no interventions imposed by the study. Throughout the study, participants treatment adherence, completion rates, delays in dosing, travel burden, and quality of life are observed and recorded. Various measures include travel burden comparisons between groups, changes in quality of life scores, and timing of neoadjuvant therapy, surgery, and adjuvant treatment initiation. The study follows participants for up to 2.25 years to assess these outcomes under real-world conditions.
Actively Recruiting
Researchers are evaluating the effects of elecoglipron compared with a placebo in adults with chronic kidney disease CKD, including those with and without type 2 diabetes mellitus T2DM. This Phase III, randomized, double-blind, placebo-controlled study includes participants who are receiving standard care treatments for CKD, including the SGLT2 inhibitor dapagliflozin. The study aims to determine whether elecoglipron can reduce the risk of kidney function decline, end-stage kidney disease, and mortality. Participants will be randomly assigned to receive either elecoglipron tablets or matching placebo tablets once daily. The study is multicenter and involves parallel groups. The treatment period and evaluation are event-driven and may last up to 4.5 years. Both study groups will continue their background therapies for CKD alongside the study medication or placebo. During the study, participants will be monitored regularly to assess kidney function, cardiovascular events, and overall health outcomes, including mortality. Researchers will measure sustained declines in estimated glomerular filtration rate eGFR, occurrence of end-stage kidney disease, cardiovascular death, heart failure hospitalizations, and other related outcomes. The study includes safety monitoring throughout the trial, which is expected to last until October 2030, with participant involvement potentially extending up to 4.5 years.
Actively Recruiting
Researchers are evaluating the effects of vicadrostat combined with empagliflozin in adults with chronic heart failure who have a reduced left ventricular ejection fraction below 40%. Participants must have been diagnosed with chronic heart failure for at least three months and be in New York Heart Association classes II to IV. The study is a phase III, randomized, double-blind trial aimed at assessing whether this combination improves outcomes compared to placebo plus empagliflozin. Participants are randomly assigned to one of two groups with equal chance one group receives vicadrostat with empagliflozin tablets, and the other receives placebo with empagliflozin tablets. The study medicines are taken once daily for about six months up to three and a half years. Participants continue their regular heart failure treatments alongside the study drugs. The study monitors participants throughout this period, which can last up to 43 months. During the study, participants attend regular visits to the study site and may receive some follow-up calls. They answer questionnaires about their symptoms and overall well-being. Doctors record any worsening heart failure symptoms, hospitalizations due to heart failure, or deaths to compare the two groups. Health status and any side effects are regularly checked. The primary outcome is the time to first cardiovascular death, hospitalization for heart failure, or urgent heart failure visit.
Actively Recruiting
Researchers are evaluating the combination of vicadrostat BI 690517 and empagliflozin for adults aged 18 and older who have heart failure symptoms and a left ventricular ejection fraction LVEF of 40% or more. The study aims to find out whether taking vicadrostat with empagliflozin helps people with heart failure. This is a phase III randomized, double-blind, parallel-group trial sponsored by Boehringer Ingelheim. Participants are randomly assigned to one of two groups one group takes vicadrostat combined with empagliflozin tablets once daily, and the other group takes a placebo combined with empagliflozin tablets once daily. The study has no fixed duration participants can stay in the study as long as they benefit from treatment and can tolerate it. During the study, participants visit their doctors regularly for health checks and monitoring. Throughout the study, participants undergo regular health assessments including monitoring for any unwanted effects. Study staff may also contact participants by phone and ask them to answer questions about their well-being. The main outcome being measured is the time to the first event of cardiovascular death, hospitalization for heart failure, or urgent heart failure visit over up to 42 months. Other outcomes include symptom scores, blood pressure changes, and kidney function. The study runs until enough data is collected to evaluate the treatments effects.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of MH002, a live biotherapeutic product made of live bacteria, for treating mild-to-moderate ulcerative colitis UC. This condition causes inflammation and sores in the gut. The study aims to confirm previous findings and test two different doses of MH002 to understand its long-term effects on UC patients who have not fully responded to standard 5-aminosalicylic acid 5-ASA treatment. Participants will be randomly assigned to one of three groups low-dose MH002, high-dose MH002, or placebo. Both doses of MH002 consist of six wildtype commensal bacterial strains and are given orally once daily in capsule form. The study will last at least 12 weeks, focusing on the induction phase, during which researchers will monitor treatment effects and safety. During the study, participants will undergo assessments including endoscopic exams to measure changes in the gut lining, histologic evaluations, fecal calprotectin tests, and symptom scores to assess disease activity. Safety and tolerability will also be closely monitored. The primary outcome is the change in Mayo Endoscopic Subscore at Week 12. Participants will be followed throughout the treatment phase, which helps researchers understand how MH002 affects UC over time.
Actively Recruiting
Researchers are evaluating the effects of vicadrostat combined with empagliflozin in adults who have type 2 diabetes, high blood pressure, and established cardiovascular disease but no history of heart failure. This study aims to understand if this combination can reduce the risk of cardiovascular events compared to a placebo combined with empagliflozin. Participation is randomized and double-blinded to compare these treatments fairly. Participants are randomly assigned to one of two groups one takes vicadrostat plus empagliflozin, and the other takes placebo tablets that look like vicadrostat plus empagliflozin. They take one tablet daily for a period ranging from two and a half years up to four years and three months. All participants continue their regular medications for diabetes, hypertension, and cardiovascular disease alongside the study treatments. Throughout the study, participants attend regular visits where their health is carefully monitored. Doctors collect information about cardiovascular events and take blood samples. They also track any side effects and changes in blood pressure and kidney function. The main outcome is the time until the first cardiovascular death or heart failure event, observed over up to 51 months. Participants stay in the study for up to four years and three months with ongoing health assessments.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of plozasiran in adults with severe hypertriglyceridemia who have experienced at least two prior acute pancreatitis episodes, with at least one occurring within the last year before screening. This phase 3, randomized, double-blind study aims to understand how plozasiran impacts the risk of acute pancreatitis in this high-risk population. Participants will be randomly assigned to receive either plozasiran 25 mg or a matching placebo through subcutaneous injections every three months during the double-blind treatment period. They are advised to maintain a low-fat diet and continue their usual lipid-lowering medications. After finishing this period or experiencing an acute pancreatitis event, participants may enter a 12-month open-label extension where all receive plozasiran injections every three months. Throughout the study, participants will undergo regular assessments including measuring the time to the first acute pancreatitis event, changes in fasting triglyceride levels, and patient-reported health and productivity questionnaires. Safety will be monitored by tracking adverse events and cardiovascular outcomes. The study duration spans up to approximately 50 months for the double-blind phase, followed by a 12-month extension, with ongoing evaluations to understand the treatments impact.